The University of Southampton
University of Southampton Institutional Repository

Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis

Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis
Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis
INTRODUCTION: EUROFORS was a 2-yr prospective, randomized trial of postmenopausal women with established osteoporosis, designed to investigate various sequential treatments after teriparatide 20 microg/d for 1 yr. The present secondary analysis examined the effects of 2 yr of open-label teriparatide in women previously treated with antiresorptive drugs for at least 1 yr.
METHODS: A subgroup of 245 women with osteoporosis who had 2 yr of teriparatide treatment were stratified by previous predominant antiresorptive treatment into four groups: alendronate (n=107), risedronate (n=59), etidronate (n=30), and non-bisphosphonate (n=49). Bone mineral density (BMD) at the lumbar spine and hip was determined after 6, 12, 18, and 24 months, and bone formation markers were measured after 1 and 6 months.
RESULTS: Significant increases in bone formation markers occurred in all groups after 1 month of teriparatide treatment. Lumbar spine BMD increased at all visits, whereas a transient decrease in hip BMD, which was subsequently reversed, was observed in all groups. BMD responses were similar in all previous antiresorptive groups. Previous etidronate users showed a higher increase at the spine but not at the hip BMD. Duration of previous antiresorptive therapy and lag time between stopping previous therapy and starting teriparatide did not affect the BMD response at any skeletal site. Treatment-emergent adverse events were similar to those reported in treatment-naive postmenopausal women with osteoporosis treated with teriparatide.
CONCLUSIONS: Teriparatide induces positive effects on BMD and markers of bone formation in postmenopausal women with established osteoporosis, regardless of previous long-term exposure to antiresorptive therapies.
peptide fragments, women, exposure, drug therapy, responses, spine, humans, adverse effects, blood, teriparatide, bone, postmenopausal, osteoporosis, aged, therapeutic use, methods, hip, female, middle aged, physiopathology, osteogenesis, therapy, analysis, procollagen, prevention & control, time, prospective studies, bone density, bone resorption, bone density conservation agents, research, drug effects
0021-972X
852-860
Boonen, Steven
fbfd999d-e425-406c-b66e-ca1b8150497b
Marin, Fernando
652cc8b1-5f3c-47f1-8c53-196eee7317b5
Obermayer-Pietsch, Barbara
f366779e-4808-4bf5-bb8e-6523b96656b9
Simoes, Maria E.
badded81-501c-4201-9514-9b702d133e48
Barker, Clare
5c44e163-1148-48ab-8356-a842f86bf4d6
Glass, Emmett V.
61c219d5-0d7b-47ea-b5b2-0b3c1706673b
Hadji, Peyman
f02862c9-2032-4888-a9c3-8e0c5761119d
Lyritis, George
0fa7ccbe-cdda-4605-902c-a80b04818b0f
Oertel, Heide
cec67d68-556f-4f74-a0dd-345e8b371580
Nickelsen, Thomas
5e00d667-8fb0-4052-ba76-309ea202b649
McCloskey, Eugene V. for the EUROFORS Investigators
3f39fc3d-3eb3-4fdb-ad1a-b3c295fce73f
Boonen, Steven
fbfd999d-e425-406c-b66e-ca1b8150497b
Marin, Fernando
652cc8b1-5f3c-47f1-8c53-196eee7317b5
Obermayer-Pietsch, Barbara
f366779e-4808-4bf5-bb8e-6523b96656b9
Simoes, Maria E.
badded81-501c-4201-9514-9b702d133e48
Barker, Clare
5c44e163-1148-48ab-8356-a842f86bf4d6
Glass, Emmett V.
61c219d5-0d7b-47ea-b5b2-0b3c1706673b
Hadji, Peyman
f02862c9-2032-4888-a9c3-8e0c5761119d
Lyritis, George
0fa7ccbe-cdda-4605-902c-a80b04818b0f
Oertel, Heide
cec67d68-556f-4f74-a0dd-345e8b371580
Nickelsen, Thomas
5e00d667-8fb0-4052-ba76-309ea202b649
McCloskey, Eugene V. for the EUROFORS Investigators
3f39fc3d-3eb3-4fdb-ad1a-b3c295fce73f

Boonen, Steven, Marin, Fernando, Obermayer-Pietsch, Barbara, Simoes, Maria E., Barker, Clare, Glass, Emmett V., Hadji, Peyman, Lyritis, George, Oertel, Heide, Nickelsen, Thomas and McCloskey, Eugene V. for the EUROFORS Investigators (2008) Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. Journal of Clinical Endocrinology & Metabolism, 93 (3), 852-860. (doi:10.1210/jc.2007-0711).

Record type: Article

Abstract

INTRODUCTION: EUROFORS was a 2-yr prospective, randomized trial of postmenopausal women with established osteoporosis, designed to investigate various sequential treatments after teriparatide 20 microg/d for 1 yr. The present secondary analysis examined the effects of 2 yr of open-label teriparatide in women previously treated with antiresorptive drugs for at least 1 yr.
METHODS: A subgroup of 245 women with osteoporosis who had 2 yr of teriparatide treatment were stratified by previous predominant antiresorptive treatment into four groups: alendronate (n=107), risedronate (n=59), etidronate (n=30), and non-bisphosphonate (n=49). Bone mineral density (BMD) at the lumbar spine and hip was determined after 6, 12, 18, and 24 months, and bone formation markers were measured after 1 and 6 months.
RESULTS: Significant increases in bone formation markers occurred in all groups after 1 month of teriparatide treatment. Lumbar spine BMD increased at all visits, whereas a transient decrease in hip BMD, which was subsequently reversed, was observed in all groups. BMD responses were similar in all previous antiresorptive groups. Previous etidronate users showed a higher increase at the spine but not at the hip BMD. Duration of previous antiresorptive therapy and lag time between stopping previous therapy and starting teriparatide did not affect the BMD response at any skeletal site. Treatment-emergent adverse events were similar to those reported in treatment-naive postmenopausal women with osteoporosis treated with teriparatide.
CONCLUSIONS: Teriparatide induces positive effects on BMD and markers of bone formation in postmenopausal women with established osteoporosis, regardless of previous long-term exposure to antiresorptive therapies.

Full text not available from this repository.

More information

Published date: March 2008
Keywords: peptide fragments, women, exposure, drug therapy, responses, spine, humans, adverse effects, blood, teriparatide, bone, postmenopausal, osteoporosis, aged, therapeutic use, methods, hip, female, middle aged, physiopathology, osteogenesis, therapy, analysis, procollagen, prevention & control, time, prospective studies, bone density, bone resorption, bone density conservation agents, research, drug effects

Identifiers

Local EPrints ID: 60926
URI: https://eprints.soton.ac.uk/id/eprint/60926
ISSN: 0021-972X
PURE UUID: 751522ef-df00-418a-aa3f-643b9a980fb9

Catalogue record

Date deposited: 19 Sep 2008
Last modified: 13 Mar 2019 20:29

Export record

Altmetrics

Contributors

Author: Steven Boonen
Author: Fernando Marin
Author: Barbara Obermayer-Pietsch
Author: Maria E. Simoes
Author: Clare Barker
Author: Emmett V. Glass
Author: Peyman Hadji
Author: George Lyritis
Author: Heide Oertel
Author: Thomas Nickelsen
Author: Eugene V. for the EUROFORS Investigators McCloskey

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×